Get the Stockscreener App
12.33
0.49%
0.06
After Hours:
12.43
0.10
+0.81%
Satellos Bioscience Inc stock is traded at $12.33, with a volume of 41,113.
It is up +0.49% in the last 24 hours and up +0.00% over the past month.
Satellos Bioscience Inc is a regenerative medicine company a biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.
See More
Previous Close:
$12.27
Open:
$12.325
24h Volume:
41,113
Relative Volume:
2.43
Market Cap:
$254.33M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+5.75%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$12.17
$12.57
1-Week Range:
$11.72
$13.39
52-Week Range:
$10.72
$13.39
Satellos Bioscience Inc Stock (MSLE) Company Profile
Name
Satellos Bioscience Inc
Sector
Industry
Phone
-
Address
-
Compare MSLE vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MSLE
Satellos Bioscience Inc
|
12.33 | 253.09M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Satellos Bioscience Inc Stock (MSLE) Latest News
(MSCL) Trading Performance and Risk Management (MSCL:CA)Stock Traders Daily Canada - Stock Traders Daily
MSCLFSatellos Bioscience Inc Latest Stock News & Market Updates - Stock Titan
(MSCL) Strategic Market Analysis (MSCL:CA) - Stock Traders Daily
Satellos Bioscience (MSLE) Stock Analysis Report | Financials & Insights - Benzinga España
Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference - BioSpace
Stocks in play: Satellos Bioscience Inc. - The Globe and Mail
Satellos Bioscience Inc. - Baystreet.ca
Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association - PharmiWeb.com
Satellos to Showcase New SAT-3247 DMD and FSHD Data at 2026 MDA Conference - TipRanks
Satellos (Nasdaq: MSLE) plans SAT-3247 data at 2026 MDA meeting - Stock Titan
(MSCL) Market Insights and Trading Signals (MSCL:CA) - Stock Traders Daily
(MSCL) Technical Analysis and Trading Signals (MSCL:CA) - Stock Traders Daily
Satellos Bioscience to Court Investors as Phase 2 DMD Program Advances - TipRanks
Satellos Bioscience (MSLE) highlights SAT-3247 at key investor conferences - Stock Titan
Satellos to Participate in Upcoming Investor Conferences - Investing News Network
Satellos to Host February 24 Virtual KOL Event Showcasing SAT-3247 in Duchenne Muscular Dystrophy - TipRanks
Satellos (NASDAQ: MSLE) sets virtual KOL event on SAT-3247 DMD program - Stock Titan
Satellos to Host Virtual KOL Event on SAT-3247 in Duchenne Muscular Dystrophy - PharmiWeb.com
Inside Satellos’ experimental DMD pill at live online event - Stock Titan
(MSCL) Equity Trading Insights (MSCL:CA) - Stock Traders Daily
US$57.2M raise and Nasdaq Global Market listing for Satellos Bioscience (NASDAQ: MSLE) - Stock Titan
1st boys dosed in Phase 2 trial of oral DMD treatment SAT-3247 - Muscular Dystrophy News
Satellos to Highlight Duchenne Drug Program at Series of Investor Conferences - TipRanks
(MSCL) Dynamic Trading Report (MSCL:CA) - Stock Traders Daily
United StatesMintz Advises Satellos Bioscience In Its US$57.2 Million Initial US Public Offering - Mondaq
Satellos Bioscience (NASDAQ:MSLE) Upgraded at Zacks Research - Defense World
Total liabilities of Satellos Bioscience Inc. – BOATS:MSLE - TradingView
Satellos Bioscience (MSLE) Stock Chart and Price History 2026 - MarketBeat
Satellos Bioscience (MSLE) Stock Trends and Sentiment 2026 - MarketBeat
Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy - Investing News Network
Satellos Bioscience Doses First Patient in Phase 2 Pediatric Duchenne Study of SAT-3247 - TipRanks
Free cash flow per share of Satellos Bioscience Inc. – BOATS:MSLE - TradingView
Satellos Bioscience Completes US$57.2 Million Cross-Border Public Offering and Nasdaq Listing - Global Legal Chronicle
This Canadian biotech stock is undervalued, analyst says - Cantech Letter
Satellos price target raised to $40 from $5 at Oppenheimer - Yahoo Finance
Satellos Closes US$57.2 Million Public Offering in Canada and the United States - 富途牛牛
Satellos to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 - PharmiWeb.com
Satellos Bioscience to Highlight Muscle-Regeneration Platform at Guggenheim Biotech Summit 2026 - TipRanks
Mintz Advises Satellos Bioscience in its US$57.2 Million Initial US Public Offering - Mintz
Satellos Bioscience Raises US$57.2 Million in Cross-Border Equity Offering to Advance Muscle Disease Pipeline - TipRanks
Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters’ Option to Purchase Additional Shares - BioSpace
Latham Advises on Satellos’ US$50 Million Initial US Offering - Legal Desire Media and Insights
Why MSLE Stock Gave Up All Nasdaq Debut Gains And Fell 8% After Hours - Stocktwits
Satellos Bioscience raises $57.2 million in public offering By Investing.com - Investing.com Canada
Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise - pharmiweb.com
Satellos Bioscience Completes $57.2 Million Public Offering - marketscreener.com
Satellos Bioscience raises $57.2 million in public offering - Investing.com
Satellos Brief: Closes US$57.2M Public Offer in Canada and United States, Including Exercise of Underwriters' Option to Purchase Additional Shares - marketscreener.com
Satellos Bioscience Inc Stock (MSLE) Financials Data
There is no financial data for Satellos Bioscience Inc (MSLE). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):